Trials / Conditions / Eye Diseases, Hereditary

Eye Diseases, Hereditary

20 registered clinical trials studyying Eye Diseases, Hereditary — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) NCT06891443	Laboratoires Thea	Phase 3
Recruiting	A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreall NCT06852963	PYC Therapeutics	Phase 1 / Phase 2
Recruiting	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH NCT06627179	Laboratoires Thea	Phase 2
Active Not Recruiting	Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study NCT06162585	Nanoscope Therapeutics Inc.	—
Active Not Recruiting	Natural History of PRPF31 Mutation-Associated Retinal Dystrophy NCT05573984	PYC Therapeutics	—
Terminated	Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon NCT05176717	Laboratoires Thea	Phase 2 / Phase 3
Terminated	Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in E NCT05158296	Laboratoires Thea	Phase 2 / Phase 3
Completed	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] NCT04945772	Nanoscope Therapeutics Inc.	Phase 2
Active Not Recruiting	Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F NCT04765345	Jaeb Center for Health Research	—
Active Not Recruiting	A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigme NCT04123626	ProQR Therapeutics	Phase 1 / Phase 2
Unknown	Single Ascending Dose Study in Participants With LCA10 NCT03872479	Editas Medicine, Inc.	Phase 1 / Phase 2
Terminated	Extension Study to Study PQ-110-001 (NCT03140969) NCT03913130	Laboratoires Thea	Phase 1 / Phase 2
Active Not Recruiting	A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in NCT03913143	ProQR Therapeutics	Phase 2 / Phase 3
Completed	Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the US NCT03780257	ProQR Therapeutics	Phase 1 / Phase 2
Completed	Natural History Study of CEP290-Related Retinal Degeneration NCT03396042	Editas Medicine, Inc.	—
Completed	Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated NCT02946879	MeiraGTx UK II Ltd	—
Unknown	Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy NCT02203682	Sun Yat-sen University	Phase 2
Recruiting	Inherited Retinal Degenerative Disease Registry NCT02435940	Foundation Fighting Blindness	—
Completed	Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy NCT01727973	Sun Yat-sen University	Phase 1 / Phase 2
Completed	Fundus Changes in the Microphthalmy Eyes NCT00811512	Hospital de Olhos Sadalla Amin Ghanem	—